MetaCap

Citius Oncology Inc. (CTOR)

NASDAQ: CTORHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.5035-0.0619 (-10.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CTOR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$53.25M
EPS (TTM)
-$0.48
52-week range
0.491 – 1.83
Day range
0.502 – 0.5698
Volume / Avg
52.63K / 114.02K
Beta
—
Next earnings
Dec 22, 2026

52-week range

$0.491$1.83

CTOR stock today

Citius Oncology (CTOR) closed at $0.5035 on Nov 20, down 10.95% (-$0.0619), versus the S&P 500's 3.70% decline. Trading was light, with 52.63K shares changing hands, about 46% of the average daily volume. At this level, CTOR sits near the bottom of its 52-week range of $0.491 to $1.83: 72.5% below the high, set on Dec 1, 2025 and 2.5% above the low.

CTOR is down 49.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.4%. Citius Oncology has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful. Citius Oncology's next earnings report is expected on Dec 22, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Citius Oncology

Company profile

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Leonard L. Mazur
Headquarters
Cranford, NJ
IPO year
2022

Financial highlights

Full financials

Citius Oncology reported a net loss of $24.8 million, compared with a loss of $21.1 million a year earlier. Diluted earnings per share came in at -$0.34.

Citius Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2023FY 2022
Revenue—————
Growth—————
Net income$-24.76M$-21.15M$2.42M$-12.70M$380.81K
EPS (diluted)$-0.34$-0.31$0.27$-0.19$0.12

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$4.00+694.44%

  • Strong buy 1
  • Buy 0
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 22, 2026
Last reported (Q3 2026)
Aug 14, 2026
EPS actual vs est.
$-0.08 vs —

CTOR news

All CTOR news

Citius Oncology peers

Health Care sector
CTOR peer companies
CompanyPrice% ChgMarket capCompare
LFVNLifevantage Corporation4.15-15.13%$52.63Mvs CTOR
XBITXBiotech Inc.1.73+2.98%$52.74Mvs CTOR
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs CTOR
ALDXAldeyra Therapeutics Inc.0.84+16.39%$50.70Mvs CTOR
CLNNClene Inc.3.52+0.57%$50.69Mvs CTOR
BOLDBoundless Bio Inc.2.32-2.52%$54.78Mvs CTOR
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs CTOR
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs CTOR

Indexes, lists and sector

Citius Oncology stock FAQ

What is Citius Oncology's stock price today?

CTOR last traded at $0.5035 as of Nov 20, 4:00 PM EST, down 10.95% on the day. Prices are delayed at least 15 minutes.

When is Citius Oncology's next earnings date?

Citius Oncology is expected to report earnings on Tuesday, December 22, 2026.

Who is Citius Oncology's CEO?

Mr. Leonard L. Mazur is the chief executive officer of Citius Oncology Inc..

What is the CTOR 52-week high?

The 52-week high for CTOR is $1.83 and the 52-week low is $0.491. The stock is currently 72.5% below its high.

Compare CTOR